Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Renin inhibitors.

W J Greenlee1

  • 1Exploratory Chemistry Department, Merck Sharp and Dohme Research Laboratories, Merck and Co., Inc., Rahway, New Jersey 07065.

Medicinal Research Reviews
|April 1, 1990
PubMed
Summary

Developing orally effective, long-acting renin inhibitors is crucial for hypertension treatment. Future nonpeptide designs promise improved bioavailability and therapeutic success over current options.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The chemistry of drug design and lead optimization. Editorial overview.

Current opinion in drug discovery & development·2009
Same author

The chemistry of drug design and lead optimization. Editorial overview.

Current opinion in drug discovery & development·2009
Same author

Editorial overview. The chemistry of drug design and lead optimization.

Current opinion in drug discovery & development·2009
Same author

Tetrahydroisoquinolines as MCH-R1 antagonists.

Bioorganic & medicinal chemistry letters·2006
Same author

SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo.

Proceedings of the National Academy of Sciences of the United States of America·2001
Same author

Discovery of 4-[(Z)-(4-bromophenyl)- (ethoxyimino)methyl]-1'-[(2,4-dimethyl-3- pyridinyl)carbonyl]-4'-methyl-1,4'- bipiperidine N-oxide (SCH 351125): an orally bioavailable human CCR5 antagonist for the treatment of HIV infection.

Journal of medicinal chemistry·2001

Area of Science:

  • Pharmacology
  • Cardiovascular Research
  • Drug Development

Background:

  • Intensive research since the 1980s targets orally effective, long-acting renin inhibitors.
  • Significant progress has been made in increasing in vitro potency, achieving subnanomolar IC50 values.
  • Inhibitor design has evolved towards smaller, more stable structures with reduced molecular weight and peptide character.

Purpose of the Study:

  • To review the development of renin inhibitors for antihypertensive therapy.
  • To highlight the challenges of limited oral bioavailability and short duration of action.
  • To explore the potential of next-generation nonpeptide inhibitors.

Main Methods:

  • Analysis of in vitro and in vivo studies on renin inhibitors.
  • Review of structural modifications leading to improved potency and stability.
  • Evaluation of clinical data for renin inhibitors in human studies.

Main Results:

  • Transition-state inhibitor designs show high in vitro potency.
  • Inhibitors have demonstrated promising in vivo activities.
  • Current renin inhibitors exhibit limited oral bioavailability and short duration of action.

Conclusions:

  • Further improvements in oral bioavailability and duration are essential for renin inhibitors to compete with ACE inhibitors.
  • Wholly nonpeptide inhibitors with lower molecular weight represent the future of renin-based therapeutics.
  • Orally effective, long-acting renin inhibitors could offer advantages in long-term antihypertensive therapy.

Related Experiment Videos